-transparent.png){kind=logo}
Eighteen adult patients with solid tumors were treated with oral menogaril, a new anthracycline antibiotic active against human breast cancer after intravenous administration. The drug was given orally on 3 consecutive days every 4 weeks at doses ranging from 50 to 175 mg/m2/day. Reversible and dose-related leukopenia was the dose-limiting toxicity. At doses from 50 to 150 mg/m2/day, non-hematologic side effects of oral menogaril were unfrequent and mild and consisted of nausea and vomiting (1 patient), alopecia (2 patients), mucositis (2 patients) and liver function test abnormalities (3 patients). The only patient treated at a daily dose of 175 mg/m2 developed grade IV leukothrombocytopenia, with fever and gastrointestinal bleeding. This was followed by heart insufficiency and the patient died from multisystem organ failure. A dose of 150 mg/m2/day for 3 consecutive days is recommended for phase II trials with oral menogaril.
P Dodion, and
D de Valeriola, and
N Crespeigne, and
B Peeters, and
F Wery, and
C van Berchem, and
J Joggi, and
Y Kenis
May 1992,
Annals of oncology : official journal of the European Society for Medical Oncology,
P Dodion, and
D de Valeriola, and
N Crespeigne, and
B Peeters, and
F Wery, and
C van Berchem, and
J Joggi, and
Y Kenis
June 1986,
Cancer treatment reports,
P Dodion, and
D de Valeriola, and
N Crespeigne, and
B Peeters, and
F Wery, and
C van Berchem, and
J Joggi, and
Y Kenis
February 1990,
Investigational new drugs,
P Dodion, and
D de Valeriola, and
N Crespeigne, and
B Peeters, and
F Wery, and
C van Berchem, and
J Joggi, and
Y Kenis
January 1996,
Investigational new drugs,
P Dodion, and
D de Valeriola, and
N Crespeigne, and
B Peeters, and
F Wery, and
C van Berchem, and
J Joggi, and
Y Kenis
May 1986,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
P Dodion, and
D de Valeriola, and
N Crespeigne, and
B Peeters, and
F Wery, and
C van Berchem, and
J Joggi, and
Y Kenis
January 1994,
European journal of cancer (Oxford, England : 1990),
P Dodion, and
D de Valeriola, and
N Crespeigne, and
B Peeters, and
F Wery, and
C van Berchem, and
J Joggi, and
Y Kenis
February 2012,
Current oncology (Toronto, Ont.),
P Dodion, and
D de Valeriola, and
N Crespeigne, and
B Peeters, and
F Wery, and
C van Berchem, and
J Joggi, and
Y Kenis
January 1982,
Journal of clinical pharmacology,
P Dodion, and
D de Valeriola, and
N Crespeigne, and
B Peeters, and
F Wery, and
C van Berchem, and
J Joggi, and
Y Kenis
November 1986,
Cancer research,
P Dodion, and
D de Valeriola, and
N Crespeigne, and
B Peeters, and
F Wery, and
C van Berchem, and
J Joggi, and
Y Kenis
November 1996,
British journal of cancer,
